Myriad Genetics, Inc. (NASDAQ:MYGN) – Analysts at Leerink Swann increased their Q1 2019 earnings per share estimates for Myriad Genetics in a research report issued on Tuesday, September 18th. Leerink Swann analyst P. Souda now forecasts that the company will post earnings per share of $0.24 for the quarter, up from their prior forecast of $0.21. Leerink Swann also issued estimates for Myriad Genetics’ Q2 2019 earnings at $0.35 EPS, Q3 2019 earnings at $0.40 EPS, Q4 2019 earnings at $0.41 EPS and FY2019 earnings at $1.40 EPS.

A number of other equities analysts have also recently issued reports on the stock. Morgan Stanley upgraded shares of Myriad Genetics from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $35.00 to $55.00 in a research report on Wednesday, July 11th. Barclays cut shares of Myriad Genetics from an “equal weight” rating to an “underweight” rating and cut their target price for the stock from $38.00 to $30.00 in a research report on Wednesday, September 5th. Zacks Investment Research cut shares of Myriad Genetics from a “buy” rating to a “sell” rating in a research report on Monday, August 27th. Bank of America lifted their target price on shares of Myriad Genetics from $20.00 to $31.00 and gave the stock an “underperform” rating in a research report on Monday, July 16th. Finally, BidaskClub cut shares of Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 21st. Four analysts have rated the stock with a sell rating, three have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Myriad Genetics presently has an average rating of “Hold” and an average target price of $39.10.

Shares of MYGN opened at $47.37 on Thursday. The company has a quick ratio of 2.86, a current ratio of 3.19 and a debt-to-equity ratio of 0.01. The stock has a market cap of $3.38 billion, a price-to-earnings ratio of 39.48, a price-to-earnings-growth ratio of 3.25 and a beta of 0.44. Myriad Genetics has a 12-month low of $27.23 and a 12-month high of $50.44.

Myriad Genetics (NASDAQ:MYGN) last announced its earnings results on Tuesday, August 21st. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.05. The company had revenue of $200.90 million during the quarter, compared to analysts’ expectations of $195.93 million. Myriad Genetics had a net margin of 17.69% and a return on equity of 9.78%. The firm’s quarterly revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.30 earnings per share.

In other news, VP Richard M. Marsh sold 70,672 shares of the business’s stock in a transaction that occurred on Wednesday, July 11th. The shares were sold at an average price of $42.88, for a total value of $3,030,415.36. Following the completion of the transaction, the vice president now owns 154,869 shares of the company’s stock, valued at $6,640,782.72. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Mark Christopher Capone sold 80,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 11th. The shares were sold at an average price of $41.00, for a total transaction of $3,280,000.00. Following the completion of the transaction, the insider now directly owns 184,948 shares of the company’s stock, valued at approximately $7,582,868. The disclosure for this sale can be found here. In the last three months, insiders sold 180,672 shares of company stock valued at $7,572,215. Company insiders own 6.70% of the company’s stock.

Large investors have recently bought and sold shares of the company. BlackRock Inc. grew its holdings in Myriad Genetics by 6.7% in the second quarter. BlackRock Inc. now owns 11,083,521 shares of the company’s stock valued at $414,192,000 after purchasing an additional 691,243 shares during the period. Frontier Capital Management Co. LLC grew its holdings in Myriad Genetics by 18.0% in the second quarter. Frontier Capital Management Co. LLC now owns 2,376,935 shares of the company’s stock valued at $88,826,000 after purchasing an additional 362,821 shares during the period. Northern Trust Corp grew its holdings in Myriad Genetics by 2.7% in the second quarter. Northern Trust Corp now owns 1,801,882 shares of the company’s stock valued at $67,337,000 after purchasing an additional 47,994 shares during the period. Russell Investments Group Ltd. grew its holdings in Myriad Genetics by 0.5% in the first quarter. Russell Investments Group Ltd. now owns 1,071,096 shares of the company’s stock valued at $31,651,000 after purchasing an additional 4,865 shares during the period. Finally, Point72 Asset Management L.P. grew its holdings in Myriad Genetics by 2.2% in the first quarter. Point72 Asset Management L.P. now owns 882,874 shares of the company’s stock valued at $26,089,000 after purchasing an additional 18,926 shares during the period.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Read More: Short Selling

Earnings History and Estimates for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.